Karyopharm Therapeutics (KPTI) News Today $0.60 -0.01 (-1.90%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.64 +0.04 (+6.78%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts Set Expectations for KPTI Q1 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for Karyopharm Therapeutics in a research report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.26) per shaFebruary 22 at 7:52 AM | marketbeat.comRoyal Bank of Canada Reaffirms "Outperform" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)Royal Bank of Canada restated an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday.February 21 at 12:01 PM | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday.February 21 at 8:09 AM | marketbeat.comBarclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)February 20 at 4:42 PM | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPSKaryopharm Therapeutics (NASDAQ:KPTI - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02.February 20 at 8:59 AM | marketbeat.comKaryopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for FundingFebruary 20 at 1:31 AM | tipranks.comKaryopharm Therapeutics (KPTI) Q4 2024 Earnings Call TranscriptFebruary 19 at 1:13 PM | finance.yahoo.comKaryopharm sees FY25 revenue $140M-$155M, consensus $165.5MFebruary 19 at 8:12 AM | markets.businessinsider.comKaryopharm reports Q4 EPS (24c), consensus (27c)February 19 at 8:12 AM | markets.businessinsider.comKaryopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company ProgressFebruary 19 at 7:30 AM | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Crosses Below 200-Day Moving Average - Here's WhyFebruary 18, 2025 | marketbeat.comAntengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the RegionFebruary 13, 2025 | prnewswire.comKaryopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025February 12, 2025 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Earns "Outperform" Rating from Royal Bank of CanadaFebruary 12, 2025 | americanbankingnews.comRBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)February 10, 2025 | markets.businessinsider.comKaryopharm Therapeutics' (KPTI) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday.February 10, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average - What's Next?February 5, 2025 | marketbeat.comKaryopharm awards stock options to top executivesFebruary 2, 2025 | msn.comKaryopharm increases authorized shares, approves reverse splitJanuary 31, 2025 | msn.comKaryopharm Therapeutics' SWOT analysis: biotech stock faces pivotal yearJanuary 27, 2025 | msn.comPiper Sandler Issues a Buy Rating on Karyopharm Therapeutics (KPTI)January 27, 2025 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedJanuary 25, 2025 | marketbeat.comBarclays PLC Has $79,000 Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Barclays PLC trimmed its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,767 shares of the company's stock afJanuary 25, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for KPTI EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the company will post eJanuary 17, 2025 | marketbeat.comEdward White Recommends ‘Buy’ on Karyopharm Therapeutics Amid Promising Outlook and Strategic DevelopmentsJanuary 15, 2025 | markets.businessinsider.comKaryopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comJane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Jane Street Group LLC trimmed its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 86.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 204,750 shares of the company's stock after selliJanuary 14, 2025 | marketbeat.comKaryopharm Therapeutics Expects Q4 Revenues Of $30 MlnJanuary 13, 2025 | markets.businessinsider.comKaryopharm Announces Preliminary Unaudited 2024 Revenue and 2025 ObjectivesJanuary 13, 2025 | prnewswire.comBarclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Barclays PLC lowered its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,767 shares of the company's stock afterJanuary 10, 2025 | marketbeat.comWhy Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?January 7, 2025 | msn.comKaryopharm Therapeutics Appoints Lori Macomber As CFOJanuary 2, 2025 | markets.businessinsider.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 2, 2025 | prnewswire.comKaryopharm Announces the Appointment of Lori Macomber as Chief Financial OfficerJanuary 2, 2025 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Fifty Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 50 Day Moving Average - Here's WhyDecember 31, 2024 | marketbeat.comKaryopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsDecember 9, 2024 | prnewswire.comKaryopharm Therapeutics Provides Endometrial Cancer Program UpdateDecember 3, 2024 | prnewswire.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short InterestKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 18,930,000 shares, a growth of 7.0% from the October 31st total of 17,690,000 shares. Based on an average trading volume of 747,500 shares, the short-interest ratio is presently 25.3 days.December 3, 2024 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | prnewswire.comKaryopharm Therapeutics IncNovember 28, 2024 | money.usnews.comKaryopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.comStockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 22, 2024 | marketbeat.comKaryopharm appoints Kristin Abate as Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Appoints New Chief Accounting OfficerNovember 21, 2024 | markets.businessinsider.comKaryopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNovember 20, 2024 | prnewswire.comKaryopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 18, 2024 | prnewswire.comGSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)GSA Capital Partners LLP increased its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 80.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,775,700 shares of the company's stockNovember 14, 2024 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.November 14, 2024 | marketbeat.comStrategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm TherapeuticsNovember 9, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?November 8, 2024 | finance.yahoo.com Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Media Mentions By Week KPTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.340.60▲Average Medical News Sentiment KPTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼173▲KPTI Articles Average Week Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aquestive Therapeutics News Today Gossamer Bio News Today Candel Therapeutics News Today Atyr PHARMA News Today Immutep News Today Olema Pharmaceuticals News Today Korro Bio News Today Neumora Therapeutics News Today Y-mAbs Therapeutics News Today Kodiak Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
